Summary & Overview
HCPCS P9043: Infusion, Plasma Protein Fraction (Human) 5% 50 ml
HCPCS Level II code P9043 denotes the infusion of a 5% human plasma protein fraction in a 50 ml preparation. This supply-oriented HCPCS code captures administration of a plasma-derived colloid used in volume support or protein replacement in clinical settings. Nationally, such codes matter for clinical supply management, billing consistency across outpatient infusion centers and hospitals, and tracking utilization of plasma-derived products.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coding intent and clinical context, alignment with typical sites of service (infusion suites, outpatient clinics, hospital outpatient departments), and the common billing modifiers associated with infusion supplies. The publication provides benchmarking context where available, notes on claim line reporting, and considerations for payers and facilities in documenting and coding plasma protein fraction infusions.
The report summarizes how P9043 is used in clinical billing workflows, highlights where additional documentation is typically required, and outlines areas where policy updates or local payer requirements may affect coverage and reimbursement. Data not available in the input are noted explicitly where applicable.
Billing Code Overview
HCPCS Level II code P9043 describes infusion of plasma protein fraction (human), 5%, 50 ml. This entry represents a packaged supply/service for administration of a 5% human plasma protein solution in a 50 milliliter vial.
-
Service type: Intravenous infusion of plasma-derived protein product
-
Typical site of service: Infusion suite, outpatient clinic, hospital outpatient department, or other settings where intravenous biologic infusions are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old male with chronic liver disease and hypoalbuminemia is admitted to the hospital with signs of intravascular volume depletion and peripheral edema. Serum albumin is 2.0 g/dL and the treating team elects to administer a plasma protein fraction (human) 5% infusion to provide temporary oncotic support and mitigate third-spacing while definitive treatment for the underlying hepatic dysfunction is initiated. The infusion is prepared as a 50 mL vial and administered intravenously in the inpatient setting under nursing supervision. Vital signs, infusion site status, and for potential hypersensitivity reactions are monitored before, during, and after administration. The clinical workflow includes: ordering the product in the electronic medical record, pharmacy verification and dispensing, bedside nurse verification and infusion set-up, baseline and post-infusion vital sign documentation, and documentation of the lot and expiration number for traceability. Typical sites of service include inpatient acute care units, observation units, and hospital outpatient infusion centers when given for short-term oncotic support. Patient-specific considerations include documented indication, allergy history, weight-based dosing or institutional protocol, and observation for signs of transfusion reaction or volume overload.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Procedure code without modifiers | Used when no special circumstances apply and the service is reported as standard. |